Live Biotherapeutics Drug Discovery Services for Hepatic Encephalopathy (HE)
Present studies of probiotics have important implications for hepatic encephalopathy (HE) treatment in clinical practice. Equipped with cutting-edge platforms and professional scientific staff in live biotherapeutics drug discovery, Creative Biolabs is committed to providing the most comprehensive solutions for next-generation probiotics (NGPs) discovery, innovative research, and development of NGPs industrialization.
Introduction of HE
HE, also known as portosystemic encephalopathy, is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both overt HE and minimal HE (MHE) significantly impair the patient’s quality of life and daily functioning and represent a significant burden on healthcare resources. The pathophysiology of hepatic encephalopathy is still uncertain, but the prevailing assumption is that different toxins, such as false neurotransmitters, natural benzodiazepines, short-chain fatty acids, and mercaptans enhance the negative effects of ammonia on the level of consciousness. Current therapeutic options include intensive supportive care, identification and correction of the precipitating causes, tailored dietary restrictions, non-absorbable disaccharides, L-ornithine-L-aspartate (LOLA), and oral antibiotics.
Probiotics for the Treatment of HE
Probiotics are live microorganisms, which when administered in adequate amounts may confer a health benefit on the host. Studies have shown that probiotics alter gut flora and lead to the elaboration of flora metabolites that influence health through direct antimicrobial effects, enhancement of mucosal barrier integrity, or immune modulation. Restoring the balance of intestinal flora by introducing probiotics for disease prevention and treatment could be beneficial to human health.
-
Previous randomized controlled trials (RCTs) have estimated the efficacy of probiotics, prebiotics, and synbiotics in patients with MHE and the results reveal that probiotic treatment is effective in decreasing endotoxin and serum ammonia levels, improving MHE, and preventing overt HE development in patients with liver cirrhosis. Several RCTs used different bacterial strains as probiotics for MHE treatment, including Lactobacillus, Bifidobacterium, Pediococcus, Streptococcus, Enterococcus, and others.
-
In other studies, Clostridium butyricum in combination with other bacteria such as Streptococcus faecalis, Bacillus mesentericus, and lactic acid bacillus as probiotics were used for MHE treatment. Improvement in abnormal psychometric parameters and a significant reduction of venous ammonia and the P300 auditory event-related potential were reported. The results indicate that probiotics containing C. butyricum and Bifidobacterium infantis can be used as effective adjuvant therapy for MHE in clinical practice.
NGPs Discovery Service at Creative Biolabs
The gut microbiota has a significant role in human health and disease. Dysbiosis of the intestinal ecosystem contributes to the development of HE that can be reversed by favorable alterations by probiotics. With top-class scientific experts and integrating state-of-the-art technologies, Creative Biolabs has pioneered the discovery of novel NGPs. Our comprehensive services include but are not limited to NGPs identification, characterization, and scale-up GMP manufacturing… With the development of more affordable genome and metagenome sequencing and more powerful tools to edit bacterial genomes, our scientists are now on the cusp of a new era in NGPs research, which allows us to develop NGPs that address specific consumer needs and issues.
The development of NGPs offers a new way to create safe, effective treatments for HE patients, presenting an opportunity to treat diseases that existing therapies are unable to effectively address. Creative Biolabs offers high-quality custom NGPs discovery and development services according to your special needs in a time-saving manner. For more detailed information, please feel free to contact us.
Reference
-
Xia, X.; et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. Journal of International Medical Research. 2018, 46(9): 3596-604.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
